key: cord-0989576-6dt7ywsk
authors: Aziz, Muhammad; Perisetti, Abhilash; Lee-Smith, Wade M.; Gajendran, Mahesh; Bansal, Pardeep; Goyal, Hemant
title: Taste Changes (Dysgeusia) in COVID-19: A systematic review and metaanalysis
date: 2020-05-05
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.05.003
sha: f5563c1afd1d85f4dee54d30e9ad1de65b1673f0
doc_id: 989576
cord_uid: 6dt7ywsk

nan

(SARS-CoV-2), originated in China and rapidly spread across the world, causing a pandemic. 1 The wellrecognized symptoms of COVID-19 include fever, cough, dyspnea, sputum production, myalgia, arthralgia, headache, diarrhea, nausea/vomiting, and sore throat. It appears that a subset of COVID-19 patients also develops other symptoms such as ageusia/dysgeusia. 2 We performed a systematic review of the available literature to assess the presence of ageusia/dysgeusia among COVID-19 patients.

We performed a systematic review of the following databases: PubMed/Medline, Embase, Cochrane, Web of Science from January 1 st -April 21 st , 2020, to identify relevant articles reporting ageusia/dysgeusia as a symptom in laboratory-confirmed COVID-19 patients. Relevant articles reporting data on ageusia/dysgeusia in the form of case series, case-control, and cohort studies were included.

Studies were excluded if it did not report the symptoms of interest, i.e., ageusia/dysgeusia. Pooled analysis (where applicable) was performed using a random-effects model and DerSimonian-Laird approach. Study heterogeneity was assessed using the I 2 statistic.

The initial search yielded a total of 33 articles, and after screening duplicates and excluding irrelevant articles, a total of five studies with 817 patients were finally included. [2] [3] [4] [5] [6] Four of these studies were single-nation studies, and one study was a multinational study from Europe. The study period ranged from January 16 th , 2020 -March 29 th , 2020. The proportion of female patients was reported in 3 studies (60.7%, 95% CI 51.3% -70.1%). We found the prevalence of ageusia/dysgeusia was 49.8% (95% CI: 8.2%

-91.5%, I 2 = 99.6%) across these five studies ( figure 1 ).

In our pooled analysis, almost half of the patients (49.8%) with COVID-19 have altered taste sensation.

Taste disorders are well known to be related to a wide variety of viral illnesses. 7 The suggested mechanism of SARS-CoV-2 causing altered taste is its ability to bind to angiotensin-converting enzyme-2 (ACE-2) receptor, which is readily expressed on multiple organ systems, including the surface of the tongue and oral cavity. The oral cavity can act as a gateway to infection and lead to the development of ageusia/dysgeusia. 8 Given the lack of access to diagnostic tests for COVID-19, particularly in the developing world, the utility of distinctive clinical features (such as ageusia/dysgeusia) in identifying patients with suspected COVID-19 is of paramount significance.

Reporting of gustatory and olfactory disturbances are subjective in nature, and COVID-19 patients (without a history of ENT disorders) should be actively evaluated for these symptoms at presentation.

Our study has multiple limitations. First, there is a lack of data comparing ageusia/dysgeusia in laboratory-confirmed COVID-19 positive and negative patients. Only one study by Bénézit et al. compared the prevalence of altered taste in COVID-19 positive and negative patients who underwent testing based on suspicion. 2 A significantly increased proportion of patients reported ageusia/dysgeusia (62% vs. 11%, OR: 7.4, p <0.01) in COVID-19 positive arm. 2 There was also a lack of studies reporting an association of ageusia/dysgeusia with severe COVID-19. Mao et al. also compared the presence of altered taste sensations in severe and non-severe COVID-19 cases. A somewhat lower prevalence of ageusia/dysgeusia was seen in severe cases and was not statistically significant (p = 0.24). 5 Second, the inclusion of observational studies can undoubtedly lead to several biases, including but not limited to selection bias, information bias, recall bias, and confounding bias. Third, no study reported the association of acute respiratory distress syndrome, mortality, ICU admission, need for a ventilator, and length of ICU stay with ageusia/dysgeusia. Significant heterogeneity was noted in our analysis of prevalence. This is likely due to the reason mentioned above, i.e., the observational nature of the study.

The data was retrospectively collected from medical files, and the presence of ageusia/dysgeusia might have been underestimated. Fourth, the presence of these symptoms may not be reported in the presence of other severe symptoms such as dyspnea, fever, productive cough, etc. Due to these reasons, the true prevalence of ageusia/dysgeusia might be significantly higher (than reported in our analysis) and should be included as a screening question for patients evaluated for suspected COVID-19.

Currently, there is weak evidence if the taste or smell changes could prognosticate COVID-19-related severity and mortality. More epidemiological studies are needed to assess the prevalence of ageusia/dysgeusia in patients with COVID-19 as well as comparing mild to moderate and severe cases.

Recognizing these distinctive clinical features can raise the suspicion of COVID-19, leading to early testing and diagnosis of the disease.

World Health Organization. Pneumonia of unknown cause -China

Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. The Lancet Infectious Diseases

Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a crosssectional study

Olfactory and gustatory dysfunctions as a clinical presentation of mild-tomoderate forms of the coronavirus disease (COVID-19): a multicenter European study

Neurologic manifestations of hospitalized patients with coronavirus disease

Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms

Inflammation and taste disorders: mechanisms in taste buds

Author names in bold designate shared co-first authorship" Figure Legends: Figure 1: Forrest plot demonstrating the pooled prevalence of ageusia/dysgeusia in patients with COVID-19